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The paper by Shubin and colleagues published in this issue of *Critical Care* describes expression of the immunomodulatory protein B and T lymphocyte attenuator (BTLA) on CD4^+^ T cells from critically ill patients with sepsis or systemic inflammatory response syndrome (SIRS) \[[@B1]\]. BTLA is a co-inhibitory protein that is expressed by T lymphocytes and interacts primarily with a tumor necrosis factor superfamily molecule termed herpes virus entry mediator \[[@B2]\]. Surface expression of BTLA is low on naive CD4^+^ T cells, but is rapidly upregulated following T-lymphocyte activation. Herpes virus entry mediator is constitutively expressed on dendritic cells, B lymphocytes, natural killer cells, natural killer T cells and γδ T cells. The interaction of herpes virus entry mediator with BTLA induces bidirectional signaling pathways that balance activation and inhibition to regulate T-lymphocyte activation \[[@B3]\]. BTLA is thus a co-inhibitory receptor that, when activated, has the potential to facilitate T-cell dysfunction during sepsis and critical illness.

Recent research has raised the concept that patients with sepsis often die from persistent primary infection or development of secondary infections due to impaired adaptive antimicrobial immunity. Otto and colleagues reported that 63% of deaths in septic patients occur more than 6 days after the diagnosis of sepsis and are associated with infection by opportunistic bacteria and fungi \[[@B4]\]. Evidence indicates that impaired T-lymphocyte function contributes to the increased susceptibility to infection during the later phases of sepsis. Several recent reports describe upregulation of co-inhibitory receptors such as cytotoxic T-lymphocyte antigen-4, programmed cell death protein-1, and lymphocyte activation gene-3 on T lymphocytes from patients with sepsis \[[@B5]-[@B7]\]. Activation of co-inhibitory receptors may induce T-cell dysfunction, exhaustion, and anergy, with subsequent inability to adequately respond to active and subsequent secondary infections. In a large-scale postmortem study, Boomer and colleagues showed widespread T-lymphocyte apoptosis and exhaustion in patients who died during the later phases of sepsis \[[@B8]\]. Most of the patients that died in Boomer and colleagues' study showed evidence of ongoing infection and increased expression of co-inhibitory receptors. These findings raise the possibility that T-cell co-inhibitory receptors, and their ligands, may serve as useful biomarkers to characterize the immunological state of patients with sepsis \[[@B9]\]. In addition, experimental studies show that blockade of co-inhibitory receptors will improve the response to opportunistic infections in the septic host \[[@B10],[@B11]\]. The latter observations have prompted interest in utilizing co-inhibitory receptor blockade as a therapeutic approach to improve antimicrobial immunity during human sepsis \[[@B12]\].

Shubin and colleagues report higher mean cell surface BTLA expression on peripheral blood CD4^+^ T cells from patients with sepsis compared with critically ill nonseptic patients. They further report higher mean surface BTLA expression on blood CD4^+^ T cells from SIRS patients that developed nosocomial infections compared with SIRS patients that remained infection free. Based on their observations, the authors propose that BTLA could serve as a biomarker to identify critically ill patients that are at risk of developing nosocomial infection as well as to differentiate critically ill patients with sepsis from those with SIRS. This is an important undertaking since the identification of biomarkers that can differentiate critically ill patient populations could positively alter patient management. Examination of their results shows an absence of infection in patients with \<80% blood BTLA^+^CD4^+^ T cells. However, most patients in their cohort had \>80% BTLA^+^CD4^+^ T cells in their blood, regardless of whether they were infected. High BTLA expression was thus poorly predictive of the presence of infection. These observations highlight the challenges associated with identifying biomarkers with strong predictive value for differentiating infected patients from non-infected patients in the ICU. Nevertheless, their findings show that critically ill patients with \<80% BTLA^+^CD4^+^ T cells are most probably infection free. If confirmed in large-scale studies, this information could be valuable in guiding patient management. One should note that a major difficulty with this approach will be standardizing acquisition parameters in flow cytometers from different institutions. Even with use of fluorescent bead standards, this can be a difficult challenge.

Shubin and colleagues performed further studies in mice to assess the impact of sepsis on BTLA expression and to determine the functional importance of BTLA in facilitating lymphocyte apoptosis. The mouse model of cecal ligation and puncture was used. BTLA was expressed by \>95% of blood and splenic T cells and B cells after sham and cecal ligation and puncture procedures. A small but significant increase in BTLA mean fluorescence intensity was observed for both cell populations by 72 hours after the induction of sepsis, indicating increased BTLA expression on individual cells. Further studies demonstrated significant lymphocyte apoptosis in the thymus and spleen after cecal ligation and puncture, which was attenuated in BTLA-deficient mice. These studies show an association between BTLA expression and sepsis-induced apoptosis and infer a possible cause and effect relationship. Previous studies by the group showed enhanced survival and decreased bacterial burden in BTLA-deficient mice after cecal ligation and puncture \[[@B13]\]. Taken together, their findings imply a functional role for BTLA in mediating sepsis-induced immunosuppression.

As noted by the investigators, the current clinical study is a small, single-institutional trial that will require large-scale follow-up to determine whether BTLA expression can serve as a useful biomarker to identify critically ill patients that are at risk of developing infection. More research is also needed to evaluate the efficacy of BTLA blockade as an approach to improve the host response to infection in vulnerable populations. Despite those limitations, the paper by Shubin and colleagues advances current knowledge regarding the impact of sepsis and critical illness on T-cell function and identifies BTLA as a potential biomarker and mediator of T-cell dysfunction in critically ill patients.
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